Jun 2019
ASCO
Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.
Nov 2018
SITC – Oral Presentation
Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma
SITC
Results from a Phase I dose escalation trial (TACTImel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma
Oct 2018
Society for Melanoma Research
Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321) together with pembrolizumab in unresectable or metastatic melanoma
Jun 2018
Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II.
